Immediate Impact

34 standout
Sub-graph 1 of 13

Citing Papers

Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes
2025 Standout
Artificial intelligence in drug development
2025 Standout
3 intermediate papers

Works of Tim Heffernan being referenced

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
2023
EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma
2019

Author Peers

Author Last Decade Papers Cites
Tim Heffernan 98 54 19 44 6 188
Robert F. Koncar 68 31 34 22 6 141
Gabrielle Ernst 177 60 7 16 5 280
Eric Vroegindeweij 105 17 20 17 9 282
Andrés López‐Hernandez 74 70 25 59 5 219
Luke A. Wylie 140 25 14 35 5 255
Antonis Kokkalis 114 17 9 15 6 159
Janson W.T. Tse 196 20 7 31 8 255
Naomi Akagi 94 30 7 23 7 223
Chelsea L. Dieck 67 13 23 46 9 162
Ailith Ewing 41 45 10 39 7 152

All Works

Loading papers...

Rankless by CCL
2026